Kazia Therapeutics
$13.709876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$13.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$1.09 (-7.41%) Today
+$0.08 (+0.59%) As of 12:00 AM UTC after-hours
Why Robinhood?
You can buy or sell KZIA and other stocks, options, and ETFs commission-free!
About KZIA
Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil.
CEO
James Garner
Employees
—
Headquarters
Sydney, New South Wales (NSW)
Founded
1994
Market Cap
144.08M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
182.33K
High Today
$14.38
Low Today
$13.30
Open Price
$14.38
Volume
228.21K
52 Week High
$15.85
52 Week Low
$2.50
KZIA Earnings
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 3, Pre-Market